Lakefront Biotherapeutics (GLPGF) Interest Coverage Ratio (2016 - 2026)
Lakefront Biotherapeutics' (GLPGF) quarterly Interest Coverage Ratio came in at 464.99 in Q1 2026, up 128.53% year-over-year from 203.47 in Q1 2025, and up 175788.26% quarter-over-quarter from 0.26 in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Interest Coverage Ratio for 11 consecutive years, with 464.99 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 128.53% year-over-year to 464.99 in Q1 2026; TTM through Mar 2026 was 0.14, a 225.12% decrease from a year earlier, with the FY2025 full-year figure at 0.1, down 191.38% from the prior year.
- Interest Coverage Ratio was 464.99 for Q1 2026 at Lakefront Biotherapeutics, up from 0.26 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 464.99 in Q1 2026 and troughed at 0.26 in Q4 2025.
- A 5-year average of 149.96 and a median of 97.59 in 2025 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio tumbled 20367.83% in 2023 and soared 675.38% in 2024, its largest moves.
- Over 5 years, Interest Coverage Ratio stood at 0.0 in 2022, then plunged by 20367.83% to 0.08 in 2023, then jumped by 48.66% to 0.04 in 2024, then sank by 519.6% to 0.26 in 2025, then surged by 175788.26% to 464.99 in 2026.
- The last three Interest Coverage Ratio figures came in at 464.99 (Q1 2026), 0.26 (Q4 2025), and 370.62 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 464.99 |
| Dec 31, 2025 | -0.26 |
| Sep 30, 2025 | 370.62 |
| Jun 30, 2025 | 97.59 |
| Mar 31, 2025 | 203.47 |
| Dec 31, 2024 | -0.04 |
| Sep 30, 2024 | 241.79 |
| Jun 30, 2024 | 419.12 |
| Mar 31, 2024 | 130.44 |
| Dec 31, 2023 | -0.08 |
| Mar 31, 2023 | 16.82 |
| Dec 31, 2022 | 0.00 |
| Mar 31, 2022 | 5.03 |
| Mar 31, 2021 | 4.48 |
| Jun 30, 2020 | 36.27 |
| Mar 31, 2020 | 1.86 |
| Dec 31, 2019 | 1.39 |
| Sep 30, 2019 | -10.17 |
| Jun 30, 2019 | 30.14 |
| Mar 31, 2019 | 22.70 |